Is Viatris Inc (VTRS) overvalued? · rev $14.74B
Viatris Inc (VTRS) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Viatris Inc (VTRS) looks expensive on cached numbers — not a short thesis.
Latest reported VTRS revenue for 2024-12-31 was $14.74B. Net income was -$634.2M. Revenue was down 4.5% from 2023-12-31 to 2024-12-31. VTRS currently screens at market cap $10.83B.
VTRS currently screens at market cap $10.83B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VTRS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VTRS stock page for the full model, not this heading.
Not investment advice.